Medicinal Chemistry of Tropical Diseases
XIth SEQT Symposium
IIIrd Spanish/Portuguese/Brazilian Meeting

November, 17-18th 2016

Scientific Program

jornadas_seqt@igm.csic.es
Thursday 17 November

8:00  Bus from hotel to GSK.
8:30-9:00  Registration
9:00-9.15  Opening of XII SEQT Mini-Symposium. IIIrd Spanish/Portuguese/Brazilian Meeting

First Session: Tuberculosis

9:15-10:15  Plenary Lecture: Charles Mowbray. Head of Drug Discovery, DNDi
“DNDi - catalysing R&D for neglected patients”
10:15-10:45  Benoit Deprez. Institut Pasteur de Lille, INSERM. Université de Lille
“Smart-1 Overcoming antibiotic resistance by reprogramming bacterial metabolism”
10:45-11:15  Coffee Break
11:15-12:15: Plenary lecture. David Barros. Head of Tuberculosis DPU, DDW, GSK
“Development of New drugs for the Treatment of MDR-TB”
“GSK693 as a novel InhA direct inhibitor: a new antitubercular drug for an old target”
12:45-13:20  Flash Poster Presentations
F1: Esther Porras ,TB DPU, DDW-GSK. “Identification of a novel antimycobacterial compound active against non-replicating M. Tuberculosis: fro hit to in vivo PoC”
F3: Mª Fernanda Rey-Stolle, CEMBIO. Facultad de Farmacia, U. CEU San Pablo. “Metabolomics approach to study time trajectory metabolic changes in lung of TB infected mice”
F4: Víctor Sebastián, Centro de Investigaciones Biológicas (CIB-CSIC). “Searching for novel drugs to treat schistosomiasis: phenotypic and target-based approaches”
F5: Maria João Gouveia, ICETA. University of Oporto. “Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer”
F7: Noelia de la Cruz, Instituto de Investigaciones Químicas (IIQ-CSIC). “Multivalent glyconanogels to inhibit viral infections”
13:20-14:30  Lunch

Second Session: Malaria

14:30-15:30  Plenary Lecture: María Mota, Molecular Medicine Institute. University of Lisbon
“The complexity and the simplicity of host-Plasmodium interactions”
15:30-16:00  Esther Fernández, Malaria DPU, DDW-GSK
“Quinazolindione series identified from TCAMS: a new anti-malarial series with potential for blocking transmission of the disease”
16:00-16:30 **Coffee Break**

16:30-17:00 **Paula Gomes**, UCIBIO-REQUIMTE, University of Oporto

“When peptide chemistry meets antimalarial drug rescuing”

17:00-17:30 **Moni Sharma**, Research Institute for Medicines and Pharmaceutical Sciences, University of Lisbon

“Identification and SAR Evaluation of a Novel Chemotype with dual stage antimalarial activity”

17:30-18:00 **Flash Poster Presentations**

**F8:** **Margarita Puente**, Malaria DPU, DDW-GSK. “Antimalarial pyrazines: from a phenotypic hit to a pre-clinical candidate”

**F9:** **Caterina Pont**, Facultad de Farmacia, U de Barcelona. “Selective inhibitors of plasmodium falciparum glucose-6-phosphate dehydrogenase as a new class of antimalarial agents”

**F10:** **Gustavo da Silva**, Research Institute of Medicines. University of Lisbon. “Synthesis and biological evaluation of a novel C2 functionalized indole against blood stage malaria”

**F11:** **Sara Palomo**, Malaria DPU, DDW-GSK “Malaria bifunctional DHFR-TS enzyme as a target for drug discovery against asexual stages of P. falciparum”

**F12:** **Paul Horrocks**, Institute for Science and Technology in Medicine. Keele University. “A validated bioluminiscense-based assay for the rapid determination of the initial rate of kill for discovery antimalarials”

**F13:** **Rosana Leiva**, Lab. de Química Farmacéutica. U. de Barcelona. “Novel thiazoles as trypanocidal agents”

18:00-18:30 **Silvia Pérez-Silanes**, Instituto de Salud Tropical, U. de Navarra.

“In vitro and in-vivo anti-trypanosoma cruzi activity of new arylamine manich base derivatives”

18:30 **Bus to hotel (for participants not attending the SEQT General Meeting)**

18:30-19:30 **SEQT Members General Meeting**

21:00 **Symposium Dinner**

**Friday 18 November**

8:30 **Bus from hotel to GSK**

**Third Session: Leishmania**

9:00-10:10 **Plenary Lecture:** **Aurea Echevarria**, Chemistry Department. Federal University of Rio de Janeiro

“Some Brazilian studies of medicinal chemistry in anti-leishmanial drugs”

10:00-10:30 **Concepción Alonso**, Dpto. Qca. Orgánica. Facultad de Farmacia, U. del País Vasco

“Design and synthesis of novel indeno[1,5]naphthyridine derivatives, topoisomerase I inhibitors with antileishmanial activity”

10:30-11:00 **Flash Poster Presentations**

**F14:** **Carmen Sanmartín**, Dpto. de Qca. Orgánica y Farmacéutica. U. de Navarra. “Selenocompounds with potent and selective activity towards leishmanial in vitro”

**F15:** **Edinéa Mendes**, Instituto de Tecnologia em Imunobiológicos. Fundação Oswaldo Cruz. “Synthesis and antileishmanial activity of novel chalcone derivatives”
F16: Javier García Marín, Dpto. de Qca. Orgánica e Inorgánica. U. de Alcalá. “Pyridazino[2,3-a]pyrrolo[1,2-c]quinoxalinium salts: potent and selective leishmanicidals that show inhibition of L. infantum trypanothione reductase and human protein tyrosine phosphatase 1B”

F17: Daniel Plano, Dpto. de Qca. Orgánica y Farmacéutica. U. de Navarra. “Topological and quantum molecular descriptors as effective tools for analysing antileishmanial activity achieved by a series of alkyl, aryl and heteroaryl diselenide derivatives”


11:00-11:30 Coffee break

11:30-12:00 Héctor de Lucio, Dpto de Biología de Sistemas, Universidad de Alcalá “α/β3-peptide foldamers with cell-penetrating capacity targeting the dimerization interface of leishmania infantum trypanothione reductase”

12:00-12:30 Tim Miles, DDW-GSK. “Collaboration makes us better: BA05 series as a novel class of anti-leishmanial”

12:30-13:00 Enmanuele Amata, Department. of Drug Science, University of Catania “Identification of novel lead compounds for sleeping sickness via preferred lead repurposing”

13:00-13:35 Flash Poster Presentations

F20: Marta Ruiz-Santaquiteria, Instituto de Química Médica (IQM-CSIC). “Design and synthesis of proteomimetics to inhibit the dimerization interface of trypanothione reductase of leishmania infantum”

F21: Verónica Alcolea, Dpto. de Qca. Orgánica y Farmacéutica. U. de Navarra. “Early preclinical studies of new selenocyanate and diselenide compounds as leishmanial agents”

F22: Pilar Manzano, DDW-GSK. “GSK-Kineto boxes-Discovering new targets, mechanism and purposes. A collaborative challenge”

F23: Belén Martínez-Gualda, Instituto de Química Médica (IQM-CSIC). “Amino acids dendrimers as a novel type of HIV and Enterovirus 71 inhibitors”

F24: Christophe Dardonville, Instituto de Química Médica (IQM-CSIC). “Mitochondrion-targeted trypanosome alternative oxidase inhibitors as chemotherapeutic agents against T. brucei”

F25: Alba Gigante, Instituto de Química Médica (IQM-CSIC). “Chikungunya virus: further steps among triazolopyrimidines inhibitors to improve potency and microsomal stability”

F26: Maria Penzo, London School of Hygiene & Tropical Medicine and Malaria DPU, GSK. “High-Throughput Screening to develop new inhibitors against P. falciparum Protein Kinase G”

13:35 Closing. Concluding remarks

14:00 Lunch